This was confirmed in a study using a human uterine xenograft tumor model expressing varying levels of MSLN, which illustrated that AR’s therapeutic response was correlated with the level of MSLN expression in the tumor cells [107]. The gene discussed is MSLN; the disease is neoplasm.